CLINICAL TRIALS

At Xalud Therapeutics, we aspire to transform the way chronic inflammatory disease is treated. Patients have waited far too long for a treatment option that addresses the underlying cause of their disease. To meet this need, we are clinically investigating our non-viral gene therapy, XT-150, in a number of conditions caused by chronic inflammation.

Clinical trials are an opportunity for patients to play an integral role in the study of new, potentially effective medicines. We are currently recruiting for clinical trials that are investigating XT-150: our non-viral gene therapy containing non-integrating therapeutic plasmid DNA, enabling local delivery directly to the site of inflammation. We have designed XT-150 to have an optimized regimen, dosing and formulation – significantly increasing the duration of its effects and staying within the site of injection.

Neuropathic Pain

  • Title: Safety and Efficacy of XT-150 for the Treatment of Neuropathic Pain

  • Status: Recruiting

  • For more information on this study, please visit ClinicalTrials.gov.

Facet Joint Osteoarthritis

  • Title: Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

  • Status: Recruiting

  • For more information on this study, please visit
    ClinicalTrials.gov.

---

Expanded Access Policy

Xalud is committed to developing promising new therapies to address the unmet medical needs of patients suffering from serious diseases and conditions. Our goal is to provide access to our medicines at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe focusing on enrollment in our ongoing clinical trials is the safest and most effective way of achieving this goal.
 
We do recognize that some patients will not be eligible for our clinical trials and may wish to access our investigational products through expanded access. At present, Xalud is evaluating the benefit/risk profile of our investigational therapies and is dedicating all resources available toward developing these therapies to support regulatory approvals. As such, Xalud is currently unable to offer expanded access use of our investigational medicines.

We encourage all patients and physicians who are interested in accessing our investigational medicines to review the information on this page about enrolling in our clinical trials.

If you have any questions, please reach out to us at medical.information@xaludthera.com. You can find further contact details our Contact page.

Xalud may revise this expanded access policy at any time.

ribbon-3.jpg